Pharmaceutical intermediates
Paricalcitol Intermediates
6 pharmaceutical intermediates for Paricalcitol. Indication: Secondary hyperparathyroidism; Chronic renal insufficiency.
About Paricalcitol
- Originator
- Abbvie
- Indication
- Secondary hyperparathyroidism; Chronic renal insufficiency
- Approved Date
- 10/21/2014
Available intermediates
6 intermediates currently listed for Paricalcitol. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| Paricalcitol | 131918-61-1 | / | / |
| (1R,3aR,7aR)-1-((2R,5S,E)-6-hydroxy-5,6-diMethylhept-3-en-2-yl)-7a-Methylhexahydro-1H-inden-4(2H)-one | 95716-68-0 | / | / |
| (3R-trans)-[2-[3,5-Bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]cyclohexylidene]ethyl]diphenyl-phosphine Oxide | 139356-39-1 | / | / |
| (1R,3aR,7aR)-1-((2R,5S,E)-6-(MethoxyMethoxy)-5,6-diMethylhept-3-en-2-yl)-7a-Methylhexahydro-1H-inden-4(2H)-one | 100858-26-2 | / | / |
| (((1R,3R)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5S,E)-6-(MethoxyMethoxy)-5,6-diMethylhept-3-en-2-yl)-7a-Methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)cyclohexane-1,3-diyl)bis(oxy))bis(tert-butyldiMethylsilane) | 1435939-17-5 | / | / |
| (1R,3R)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5S,E)-6-(MethoxyMethoxy)-5,6-diMethylhept-3-en-2-yl)-7a-Methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)cyclohexane-1,3-diol | 1023889-38-4 | / | / |
Building toward Paricalcitol?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →